Your session is about to expire
← Back to Search
BT7480 + Nivolumab for Cancer
Study Summary
This trial is testing a new drug, BT7480, to see if it's safe and effective for treating cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an autoimmune disease, but it's not diabetes, alopecia, thyroid disease, or vitiligo.My diabetes is not under control, with an HbA1c level of 8% or higher.I haven't had chemotherapy or similar treatments in the last 14 days.My cancer is confirmed to be linked with Nectin-4 expression.My advanced cancer does not respond to standard treatments.I haven't had immunotherapy or monoclonal antibodies in the last 28 days or 5 half-lives, whichever is shorter.My cancer has spread and can be measured by standard tests.I can provide a recent or stored sample of my tumor.I am mostly active and my organs and blood are functioning well.I have brain metastases that are not well-managed.I have been treated with CD137 targeted therapy before.My blood pressure is not controlled with medication.
- Group 1: BT7480 monotherapy in patients with renal insufficiency
- Group 2: BT7480 and nivolumab dose expansion
- Group 3: BT7480 monotherapy dose escalation
- Group 4: BT7480 and nivolumab dose escalation
- Group 5: BT7480 monotherapy dose expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the main goals of this clinical trial?
"The primary objective of this study, which will be monitored over a period of approximately 6 months from Cycle 1 Day 1 through study completion, is to confirm the response rate as measured by the clinical benefit rate (CBR) to demonstrate clinical activity following treatment with BT7480 in the dose expansion phase. Secondary objectives include progression free survival time in the dose escalation and dose expansion phases, which are defined as the duration of time from first drug administration to disease progression according to RECIST 1.1 criteria following treatment with BT7480 alone or in combination with nivolumab, and in patients with renal insufficiency; confirmed response rate"
How many places are conducting this trial?
"There are 7 sites that are participating in this study. For example, Columbia University Irving Medical Center is based in New york while Fox Chase Cancer Center is in Philadelphia. MD Anderson Cancer Center is located in Houston and there are 4 other centres."
Why do people usually take BT7480?
"BT7480 is a medication that oncologists can prescribe to patients with malignant neoplasms. Additionally, this drug helps people who have metastatic esophageal adenocarcinoma, unresectable melanoma, and squamous cell carcinoma."
Is this a new kind of clinical trial?
"To date, there have been 747 active clinical trials for BT7480 across 2347 cities and 50 countries. The first trial was sponsored by Medarex and took place in 2010 with 127 patients. The study completed its Phase 1 drug approval stage. In the decade since the first trial, 249 more studies have been conducted."
Are researchers currently looking for more participants for this trial?
"The most recent update on clinicaltrials.gov suggests that this research is recruiting patients as of right now. The study was originally posted on November 2nd, 2021 and updated August 16th, 2022."
What is the previous research on BT7480?
"The first clinical trials for BT7480 were completed in 2010 at H. Lee Moffitt Cancer Center and Research Institute. To date, there have been a total of 249 completed clinical trials. Presently, 747 active trials are underway with many of these taking place in New york City."
How many people are willing to try this new medication?
"This clinical trial requires 200 eligible patients in order to commence. The sponsor, BicycleTx Limited, plans to run the study from several locations including Columbia University Irving Medical Center and Fox Chase Cancer Center."
Share this study with friends
Copy Link
Messenger